Tempest TherapeuticsFRA:3OS0 32 PB Ratio is 116.38 as of Jul. 02, 2026. GuruFocus rates FRA:3OS0 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,229 Biotechnology companies, Tempest Therapeutics ranks worse than 92.6% on this metric.
The historical rank and industry rank for Tempest Therapeutics's PB Ratio or its related term are showing as below:
FRA:3OS0'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 19.47
Current: 19.47
During the past 6 years, Tempest Therapeutics's highest PB Ratio was 19.47. The lowest was 0.00. And the median was 0.00.
FRA:3OS0's PB Ratio is ranked worse than 92.6% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs FRA:3OS0: 19.47
During the past 12 months, Tempest Therapeutics's average Book Value Per Share Growth Rate was -76.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -60.80% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Tempest Therapeutics was -56.30% per year. The lowest was -60.80% per year. And the median was -58.55% per year.
Back to Basics: PB Ratio
Tempest Therapeutics (FRA:3OS0) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tempest Therapeutics PB Ratio Related Terms
Tempest Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Tempest Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tempest Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tempest Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Tempest Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tempest Therapeutics (FRA:3OS0) has a PB Ratio of 116.38 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tempest Therapeutics and its competitors. According to the industry distribution chart, Tempest Therapeutics ranks #1138 out of 1229 companies in the Biotechnology industry, placing it in the top 92.6%.
Is Tempest Therapeutics' PB Ratio too high?
Tempest Therapeutics' current PB Ratio is 116.38. The Biotechnology industry median PB Ratio is 2.87. Tempest Therapeutics' value of 116.38 is 3955.1% above this industry median. Based on the distribution chart, Tempest Therapeutics ranks #1138 out of 1229 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' PB Ratio compare to HOWL and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #1138 out of 1229 companies for PB Ratio. This places Tempest Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.87. Tempest Therapeutics' value of 116.38 is 3955.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tempest Therapeutics's current PB Ratio of 116.38 is 3955.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tempest Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tempest Therapeutics's current PB Ratio is 116.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (FRA:3OS0) has a current PB Ratio of 116.38. The current PB Ratio is 116.38 and 3955.1% above the Biotechnology industry median of 2.87. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tempest Therapeutics (FRA:3OS0), the current PB Ratio is 116.38 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score
Get the complete analysis for FRA:3OS0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3OS0 has been successfully added to your 
